Clinical Trial

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 9, 2025 (before its estimated December 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to see how a medicine called PF-08049820 affects how other medicines move through the body. This information will help plan future studies. The other medicines include: * Birth control pills (containing ethinyl estradiol and levonorgestrel) * Midazolam (used to help people relax or sleep) * Dabigatran etexilate (used to prevent blood clots) This study is seeking participants who: * are female and are 18 years or older * weigh more than 110 pounds (50 kg) * have a healthy body weight (not too low or too high) * are generally healthy with no serious medical problems. People with serious health problems, recent medicine use, or who had certain vaccines recently cannot join. * are willing to follow all the study rules The study has 6 parts, and each part happens one after the other. In the first 3 parts, participants take just one dose of each medicine (midazolam, dabigatran, and birth control pills) to see how these medicines work alone. In the last 3 parts, they take PF-08049820 twice a day, along with one of the other medicines, to see how PF-08049820 changes the way those medicines move through the body. The whole study will take about 12 to13 weeks and participants will stay overnight in the clinic for about 25 days.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-09-16; most recent amendment 2025-12-08.
Status change: Recruiting → Active, Not Recruiting 2025-11-17
Status change: Not Yet Recruiting → Recruiting 2025-10-17
Trial Details
NCT Number NCT07190430
Lead Sponsor Pfizer
Conditions Atopic Dermatitis
Enrollment 16 participants
Start Date 2025-10-03
Primary Completion 2025-12-15 (estimated)
Study Completion 2025-12-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-09